News 2024-08-27
Connect with Porton at CPhI Europe 2024 @ Booth 5C17
CPhI Europe (October 8-10) in Milan, Italy, stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. At this year's exhibition, Porton will showcase its end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing and the differentiated advantages it offers to customers. From new drug development and process optimization to commercial manufacturing, Porton is dedicated to addressing customer needs and delivering efficient CDMO solutions at the highest quality and service levels. Our expertise spans from small molecules (DS-DP) to Tides, Biologics, and Conjugates.
With more than 62,000 professionals and 2,400 exhibitors hailing from over 166 countries, CPhI Europe is celebrated as one of the world's largest pharmaceutical trade show. This event serves as an unparalleled platform for powerful networking, fostering collaborations, and driving forward the pharmaceutical sector's growth and innovation.
For onsite meeting appointments, please contact: business@portonpharma.com.
Others
More
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.

News 2025-07-31
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
Overcoming the challenge of efficient synthesis of PKMYT1 inhibitor Lunresertib